Adrenocortical Carcinoma Clinical Trial
Official title:
Using New Approaches for Genomics Studies in Pediatric Adrenocortical Tumors: Whole Genome Sequencing; Deep Sequencing; miRNA; methDNA and SNP 6.0
Verified date | May 2016 |
Source | Children's Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Observational |
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the
laboratory may help doctors learn more about changes that occur in DNA and identify
biomarkers related to cancer.
PURPOSE: This research trial studies genes in samples from younger patients with
adrenocortical tumor.
Status | Completed |
Enrollment | 10 |
Est. completion date | |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 21 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Banked tumor and blood samples obtained from patients enrolled on COG-ARAR0332 in North America and Brazil PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified |
Observational Model: Case-Only, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Children's Oncology Group | National Cancer Institute (NCI) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of genetic factors affecting adrenocortical tumors | No | ||
Primary | Comprehensive catalog of altered genes in adrenocortical samples | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04373265 -
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
|
Phase 1 | |
Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
Recruiting |
NCT06066333 -
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
|
Phase 2 | |
Recruiting |
NCT03127774 -
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
|
Phase 2 | |
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Recruiting |
NCT00457587 -
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
|
||
Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
Recruiting |
NCT05999292 -
Phase 1 Study of 68Ga-R8760
|
Phase 1 | |
Completed |
NCT05361083 -
First-in-human Evaluation of [18F]CETO
|
Early Phase 1 | |
Recruiting |
NCT05660889 -
Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
|
||
Completed |
NCT00003038 -
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|
||
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Enrolling by invitation |
NCT05036434 -
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
|
Phase 2 | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06333314 -
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
|
Phase 2 | |
Withdrawn |
NCT00469469 -
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
|
Phase 2 | |
Completed |
NCT00002608 -
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05839886 -
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
|
||
Recruiting |
NCT05634577 -
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
|
Phase 2 |